{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T17:16:53Z","timestamp":1779902213205,"version":"3.53.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> The role of antihypertensive drugs in inducing hyperuricaemia and gout has been a long-term concern in clinical practice. However, clinical studies regarding this issue are limited in number and have yielded inconsistent results. We comprehensively evaluated the association between various antihypertensive drugs and the occurrences of hyperuricaemia, gout and related adverse events (AEs) using the FDA Adverse Event Reporting System (FAERS), aiming to guide the selection of antihypertensive drugs with a goal of minimizing the risk of hyperuricaemia, gout and related AEs.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> We used OpenVigil 2.1 to query the FAERS database. Hyperuricaemia, gout and related AEs were defined by 5 Preferred Terms: hyperuricaemia, gout, gouty arthritis, gouty tophus and urate nephropathy. Disproportionality analysis was performed, and a positive signal indicated an association between AEs and antihypertensive drugs.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The numbers of antihypertensive drugs with positive signals for hyperuricaemia, gout, gouty arthritis, gouty tophus and urate nephropathy were 46, 66, 27, 8 and 6, respectively. These drugs included diuretics, antihypertensive drugs with central action, \u03b1 blockers, \u03b2 blockers, \u03b1 and \u03b2 blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, renin inhibitors, vasodilators, and compound preparations. Furthermore, 42 antihypertensive drugs had positive signal for more than one AEs.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Our study suggests that some potassium-sparing diuretics, calcium channel blockers and losartan may be associated with increased risk of hyperuricaemia, gout or related AEs, which is inconsistent with most previous studies. Moreover, Our study also suggests that some antihypertensive drugs with central action, \u03b1 and \u03b2 blockers, renin inhibitors and vasodilators may be associated with increased risk of hyperuricaemia, gout or related AEs, which has not been reported in previous studies. These findings complement real-world evidence on the potential risks of hyperuricaemia, gout and related AEs associated with antihypertensive drugs.<\/jats:p>","DOI":"10.3389\/fphar.2022.1045561","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T09:36:24Z","timestamp":1673256984000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system"],"prefix":"10.3389","volume":"13","author":[{"given":"Xue-Feng","family":"Jiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunpeng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1093\/rheumatology\/kew293","article-title":"Drug-induced hyperuricaemia and gout","volume":"56","author":"Ben Salem","year":"2017","journal-title":"Rheumatol. Oxf."},{"key":"B2","article-title":"Using the OpenVigil 2 pharmacovigilance tool for guidance for clinical decisions involving newly occurring adverse events","author":"B\u00f6hm","year":"2016","journal-title":"GPTS Congr"},{"key":"B3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nbt.2113","article-title":"OpenVigil-free eyeballs on AERS pharmacovigilance data","volume":"30","author":"Bohm","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/art.38203","article-title":"Use of diuretics and risk of incident gout: A population-based case-control study","volume":"66","author":"Bruderer","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"d8190","DOI":"10.1136\/bmj.d8190","article-title":"Antihypertensive drugs and risk of incident gout among patients with hypertension: Population based case-control study","volume":"344","author":"Choi","year":"2012","journal-title":"BMJ"},{"key":"B6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/HJH.0b013e328365b916","article-title":"Association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: Data from the brisighella heart study","volume":"32","author":"Cicero","year":"2014","journal-title":"J. Hypertens."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.2174\/138161205774913309","article-title":"Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia","volume":"11","author":"Daskalopoulou","year":"2005","journal-title":"Curr. Pharm. Des."},{"key":"B8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/jamia\/ocv063","article-title":"Use of data mining at the food and drug administration","volume":"23","author":"Duggirala","year":"2016","journal-title":"J. Am. Med. Inf. Assoc."},{"key":"B9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B10","unstructured":""},{"key":"B11","unstructured":""},{"key":"B12","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1097\/BOR.0000000000000033","article-title":"Serum uric acid and the risk of hypertension and chronic kidney disease","volume":"26","author":"Feig","year":"2014","journal-title":"Curr. Opin. Rheumatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3760\/cma.j.cn112138-20200505-00449","article-title":"Practice guideline for patients with hyperuricemia\/gout","volume":"59","author":"Huang","year":"2020","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"B14","doi-asserted-by":"publisher","first-page":"11955","DOI":"10.1038\/s41598-020-68906-2","article-title":"Ovary and uterus related adverse events associated with statin use: An analysis of the FDA adverse event reporting system","volume":"10","author":"Jiao","year":"2020","journal-title":"Sci. Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.21037\/atm-20-3458","article-title":"Survey on uric acid in Chinese subjects with essential hypertension (SUCCESS): A nationwide cross-sectional study","volume":"9","author":"Liu","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/art.33315","article-title":"Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: The atherosclerosis risk in communities cohort study","volume":"64","author":"McAdams DeMarco","year":"2012","journal-title":"Arthritis Rheum."},{"key":"B17","unstructured":"2022"},{"key":"B18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"B19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/IBPC.S184685","article-title":"Hyperuricemia and hypertension: Links and risks","volume":"12","author":"Stewart","year":"2019","journal-title":"Integr. Blood Press Control"},{"key":"B20","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1055\/s-0042-113183","article-title":"Effect of antihypertensive drugs on uric acid metabolism in patients with hypertension: Cross-sectional cohort study","volume":"66","author":"Ueno","year":"2016","journal-title":"Drug Res. (Stuttg)."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 international society of hypertension global hypertension practice guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1161\/01.hyp.36.6.1072","article-title":"Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study","volume":"36","author":"Verdecchia","year":"2000","journal-title":"Hypertension"},{"key":"B23","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.amjmed.2011.09.033","article-title":"Comorbidities of gout and hyperuricemia in the US general population: Nhanes 2007-2008","volume":"125","author":"Zhu","year":"2012","journal-title":"Am. J. Med."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1045561\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T09:36:31Z","timestamp":1673256991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1045561\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":23,"alternative-id":["10.3389\/fphar.2022.1045561"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1045561","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"article-number":"1045561"}}